Immuneering Corporation

IMRX · Nasdaq · United States

Share price · IMRX

$3.50-1.53 (-30.42%) 3M

close as of 2026-11-18 · 24h delayed · vol 731K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IMRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+5.5%
  2. 6 Nov 2026+9.2%
  3. 30 Oct 2026-6.8%
  4. 11 Sep 2026-6.6%
  5. 1 Jun 2026-22.1%
  6. 29 May 2026+14.0%
  7. 28 Apr 2026-9.2%
  8. 23 Apr 2026+4.1%
  9. 14 Apr 2026-5.1%
  10. 8 Jan 2026-43.2%

Share of unusual movement by asset

For each asset, the share of IMRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Atebimetinib
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—39%
Sessions with no dated event—59%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
MEK (MAP2K1/2)Small molecule
Non-Small Cell Lung CancerPancreatic Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
AtebimetinibPhase 1/2Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
Est. primary completion 2027-06 · NCT05585320 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
AtebimetinibPhase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma …
Est. primary completion 2028-06 · NCT07562152 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
AtebimetinibPhase 2NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell Cancer …
Est. primary completion 2029-05 · NCT07946848 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026PresentationAtebimetinibPhase 2a (NCT05585320) first-line pancreatic data at ASCO 2026: median overall survival 17.3 months (n=55)

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$21M$58M+ $87M short-term inv.$24M-$17M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$14M$41M+ $109M short-term inv.$17M-$17M operating cash flowreport ↗
2026-Q1—$11M$47M+ $109M short-term inv.$13M-$18M operating cash flowreport ↗
2025-Q3—$11M$228M$15M-$12M operating cash flowreport ↗
2025-Q2—$10M$26M$14M-$9.4M operating cash flowreport ↗
2025-Q1—$11M$36M+ $0 short-term inv.$15M-$14M operating cash flowreport ↗
2024-Q3—$11M$45M+ $5.5M short-term inv.$15M-$13M operating cash flowreport ↗
2024-Q2—$11M$60M+ $0 short-term inv.$14M-$12M operating cash flowreport ↗
2024-Q1—$11M$66M+ $5.0M short-term inv.$14M-$15M operating cash flowreport ↗
2023-Q3$0$10M$68M+ $29M short-term inv.$13M-$12M operating cash flowreport ↗
2023-Q2$0$9.4M$104M+ $5.0M short-term inv.$12M-$11M operating cash flowreport ↗
2023-Q1$0$10M$77M+ $14M short-term inv.$14M-$14M operating cash flowreport ↗
2022-Q3<$0.1M$9.4M$76M+ $41M short-term inv.$13M-$11M operating cash flowreport ↗
2022-Q2$0.1M$8.0M$88M+ $40M short-term inv.$12M-$9.4M operating cash flowreport ↗
2022-Q1$0.2M$9.1M$75M+ $63M short-term inv.$13M-$12M operating cash flowreport ↗
2021-Q3$0.5M$6.2M$107M+ $43M short-term inv.$8.5M-$9.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$42M$129M+ $44M short-term inv.$14M-$45M operating cash flowreport ↗

For fiscal 2025, Immuneering reported no disclosed revenue, with R&D spend of $42.05M, down 12.3% YoY from $47.96M. Cash and equivalents were $128.65M, and the company reported a net loss of $56.02M, with quarterly net burn of $56.02M.

The company is focused on advancing atebimetinib, its lead Deep Cyclic Inhibitor, and is initiating the global Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer, with first dosing expected in mid-2026. Interim Phase 2a data for atebimetinib combined with modified gemcitabine/nab-paclitaxel showed 64% overall survival at 12 months in the initial intent-to-treat population. Immuneering also entered clinical supply agreements with Regeneron for Libtayo and Eli Lilly for olomorasib, while pausing further internal advancement of envometinib to prioritize atebimetinib. Near-term milestones include updated survival data from the pancreatic cancer cohort and updated circulating tumor DNA data in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$48M$36M+ $0 short-term inv.$15M-$55M operating cash flowreport ↗
2023-FY$0$42M$59M+ $26M short-term inv.$13M-$49M operating cash flowreport ↗
2022-FY$0.3M$36M$73M+ $33M short-term inv.$13M-$44M operating cash flowreport ↗
2021-FY$2.1M$27M$75M+ $74M short-term inv.$8.4M-$31M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 8 purchases ($360K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Gengos Andrew · Chief Financial OfficerOpen-market purchase25,000$3.58$90KForm 4
2026-11-09Bogle Grant C. · directorAward / grant (derivative)66,700——Form 4
2026-07-16Gengos Andrew · Chief Financial OfficerAward / grant (derivative)650,000——Form 4
2026-06-23Zeskind Benjamin J. · director, PRESIDENT AND CEOOpen-market purchase2,400$4.56$11KForm 4
2026-06-15Hall Brett Matthew · CHIEF SCIENTIFIC OFFICEROpen-market purchase6,035$4.15$25KForm 4
2026-06-11Feinberg Peter · directorAward / grant (derivative)33,350——Form 4
2026-06-11KEATING LAURIE · directorAward / grant (derivative)33,350——Form 4
2026-06-11CARPENTER ROBERT J · directorAward / grant (derivative)33,350——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 94 reporting institutions held 29.2M shares ($143.2M).

#InstitutionSharesValue
1FMR LLC9,697,938$51.1M
2Sanofi2,708,559$14.3M
3VANGUARD CAPITAL MANAGEMENT LLC2,288,341$12.1M
4MARSHALL WACE, LLP1,996,585$10.5M
5BlackRock, Inc.1,507,258$7.9M
6MILLENNIUM MANAGEMENT LLC1,102,712$5.8M
7GEODE CAPITAL MANAGEMENT, LLC637,944$3.4M
8Occam Crest Management LP545,098$2.9M
9CITADEL ADVISORS LLC447,278$2.4M
10Connor, Clark & Lunn Investment Management Ltd.400,363$2.1M
11Summit Financial, LLC376,749$2.0M
12UBS Group AG376,284$2.0M
13GOLDMAN SACHS GROUP INC327,655$1.7M
14VANGUARD FIDUCIARY TRUST CO322,038$1.7M
15Burkehill Global Management, LP300,000$1.6M